-
Nature sub-journal: Supplementing intestinal flora may improve the efficacy of immunotherapy!
Time of Update: 2022-04-26
Recently, the internationally renowned medical journal Nature Medicine published a study exploring the effect of bifidobacteria supplements (CBM588) on the efficacy of RCC immunotherapy.
Zhang Hailiang: This study is a phase I clinical study comparing the efficacy of nivolumab and ipilimumab with or without bifidobacteria supplementation (CBM588) in the treatment of patients with metastatic RCC .
-
Helicobacter pylori is prone to cause gastric cancer. The following 3 points should be paid attention to in the treatment!
Time of Update: 2022-04-26
According to the "Fifth National Consensus Report on the Treatment of Helicobacter pylori Infection", the recommended empirical bismuth quadruple therapy regimen (bismuth + PPI + antibiotics) is 14 days, with a minimum of 10 days .
-
ASCT is a Safe and Effective Consolidation Treatment Option for Transplanted Elderly NDMM Patients
Time of Update: 2022-04-26
The median PFS of elderly patients with TE-ASCT was significantly better than that of elderly patients with TE-non-ASCT or TNE (Fig.
9 months for patients in the TE-ASCT, TE-non-ASCT, and TNE groups, respectively (Figure 3A) .
-
2022 ELCC Voice of China: List of three blockbuster studies of camrelizumab
Time of Update: 2022-04-26
Caicun Zhou: Update on OS results of the CameL-sq study Background: The CameL-sq study is a phase III study in China to evaluate camrelizumab + chemotherapy versus placebo + chemotherapy in patients with advanced squamous NSCLC efficacy and safety .
-
It turned out that the cancer cells climbed into the tissue like "Octopus Brother"...
Time of Update: 2022-04-26
In a new study published today in Nature Communications, a research team from the University of Copenhagen in Denmark used "optical tweezers" to reveal the fundamental mechanism of all living cells: they use octopus-like "tentacles" to explore their surroundings and invade organization .
-
The pivotal Phase 3 clinical results of Express IL-2 receptor-targeted therapy are positive, and a marketing application is expected to be submitted this year
Time of Update: 2022-04-25
▎WuXi AppTec content team editors Today, Citius Pharmaceuticals announced that its investigational therapy I/ONTAK (E7777) has achieved positive top line in a pivotal Phase 3 clinical trial in patients with persistent or relapsed cutaneous T-cell lymphoma (CTCL).
-
Biositu/Yuhe Pharma Announces the Completion of the First Patient Dosing in the Australian Phase I Clinical Study of Its CD40 mAb YH003 Combined with CTLA-4 mAb YH001 and PD-1 mAb
Time of Update: 2022-04-25
Yimaike's recent hot reports ★Two "blockbusters", marketed ADC drugs are leading the way ★Biosetu/Youhe international clinical research has entered a new journey: 4-1BB monoclonal antibody completed
-
The FGFR inhibitor introduced by Express Innovent Bio was approved in mainland China for the treatment of cholangiocarcinoma
Time of Update: 2022-04-25
▎WuXi AppTec content team reported that on April 6, the official website of the China National Medical Products Administration (NMPA) announced that the FGFR1/2/3 inhibitor pemigatinib introduced by Innovent Biotech from Incyte has been approved listed .
-
PARP inhibitor Rubraca (rucaparib) in first-line treatment of advanced ovarian cancer significantly prolongs PFS
Time of Update: 2022-04-24
ovarian cancerClovis Oncology, a pharmaceutical company, today announced that its PARP inhibitor Rubraca (rucaparib) significantly extended progression-free survival compared to placebo in first-line maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer (PFS) .
-
Front Oncol: Combined radiotherapy on the basis of chemotherapy can improve the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma
Time of Update: 2022-04-24
The aim of this study was to evaluate the efficacy of chemotherapy combined with radiotherapy (CRT) versus chemotherapy alone (CT) in patients with locally advanced or metastatic esophageal squamous cell carcinoma .
-
Nano Letters: Peking University makes progress in tumor nanovaccine research!
Time of Update: 2022-04-24
Recently, the academic journal Nano Letters published online the latest research results of Wang Yiguang's research team from the State Key Laboratory of Natural and Biomimetic Medicine, School of Pharmacy, Peking University, "A pH-/enzyme-responsive nanoparticle selectively targets endosomal Toll-like receptors to potentiate robust cancer vaccination.
-
Clin Cancer Res: Long-term outcomes of second-line nivolumab in advanced esophageal cancer
Time of Update: 2022-04-24
Nivolumab has a long-term overall survival advantage over chemotherapy as second-line therapy for previously treated advanced esophageal cancer .
Nivolumab has a long-term overall survival advantage over chemotherapy as second-line therapy for previously treated advanced esophageal cancer .
-
Phase III clinical trial of Keytruda combined with PARP inhibitor failed!
Time of Update: 2022-04-24
On March 15, Merck announced the combination therapy of PD-1 monoclonal antibody Keytruda (pembrolizumab) and PARP inhibitor Lynparza (olaparib) for metastases that progressed after chemotherapy and abiraterone or enzalutamide treatment Phase III KEYLYNK-010 study in men with castration-resistant prostate cancer (mCRPC) failed to meet dual primary endpoints of OS and radiographic PFS (rPFS) at interim analysis, and was also associated with grade 3-5 adverse event rates related to the improvement .
-
JAMA Dermatol: Incidence and Mortality of Skin Melanoma Worldwide 2020
Time of Update: 2022-04-24
Geographical differences in melanoma mortality are not as large as incidence rates Geographical differences in melanoma mortality are not as large as incidenceThis epidemiological assessment shows that melanoma remains an important challenge for cancer control and public health globally, especially in Caucasian populations of European ancestry .
-
Essential for Oncologists: Subdivision of Mediastinal Lymph Nodes (IASLC)
Time of Update: 2022-04-24
Upper bound: superior border of manubrium, lower bound: tracheal carinaIASLC map(4)IASLC map(4)Lymph nodes in group 4 (lower paratracheal) are similar to group 2 and are also located around the trachea, but caudal to the plane of the aortic arch .
-
European Radiology: Relationship between preoperative needle biopsy technique and ipsilateral pleural recurrence in stage I lung cancer
Time of Update: 2022-04-24
1007/s00330-021-08359-xMin Gwan Kim Bo Ram Yang Chang Min Park ,et al Preoperative percutaneous needle lung biopsy techniques and ipsilateral pleural recurrence in stage I lung cancer.
-
Cancer: Korean multicenter real-world study evaluating long-term clinical outcomes of immunotherapy in advanced or metastatic non-small cell lung cancer (NSCLC): KCSG LU20-11
Time of Update: 2022-04-24
To assess long-term survival outcomes in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have completed 2 years of immunotherapy (ICI) or been discontinued after 6 months of immunotherapy without progression .
-
Which meat is the most friendly to people at high risk of colorectal cancer?
Time of Update: 2022-04-24
Higher total meat intake was found to be positively associated with the prevalence of rectal polyps in the fully adjusted model [OR Q4vs.
Higher total meat intake was found to be positively associated with the prevalence of rectal polyps in the fully adjusted model [OR Q4vs.
-
Brit J Cancer: Anticancer therapy linked to epigenomic changes in childhood cancer survivors
Time of Update: 2022-04-24
In a study published in the British Journal of Cancer, an authoritative journal in the field of oncology, researchers aimed to investigate the association between anticancer treatment and long-term DNA methylation changes, which may be responsible for adverse late-stage health effects in patients with CCS.
-
Lancet Oncol: Efficacy and safety of the ADC drug Anetumab ravtansine in the treatment of malignant pleural mesothelioma
Time of Update: 2022-04-24
Patients 18 years of age and older with unresectable locally advanced or metastatic mesothelin-overexpressing malignant pleural mesothelioma who progressed on first-line platinum + pemetrexed ± bevacizumab therapy were recruited, randomized 2:1 The group received intravenous Anetumab ravtansine (6.
